To investigate whether mannose enhanced the anti-tumor effect of PLX4032 in BRAF-mutated ATC, we treated the BRAF-mutated ATC cell lines 8305C and 8505C with increasing doses of PLX4032, both with and without mannose supplementation. The gene discussed is BRAF; the disease is neoplasm.